Mounjaro’s Big Win: One Shot, ₹100 Crore, Zero Competition

Mounjaro’s meteoric rise in India’s pharma market  
In a landmark shift, Mounjaro—Eli Lilly’s injectable therapy for obesity and type 2 diabetes—has emerged as India’s highest-selling drug by value for October 2025. Launched just seven months ago, the drug has rapidly gained traction among India’s affluent and health-conscious consumers, signaling a major transformation in the country’s pharmaceutical landscape.

Mounjaro contains tirzepatide, a novel compound that regulates blood sugar and slows digestion, aiding weight loss. Despite selling only 85 units in October, its high price point helped it surpass GSK’s Augmentin, which sold over 5,700 units but generated ₹80 crore in revenue.

Major takeaways:

• Mounjaro posted ₹100 crore in October sales, topping India’s pharma charts by value  
• Cumulative sales since its March 2025 launch have reached ₹333 crore  
• Augmentin remains top by volume but was dethroned in monthly revenue rankings  
• India’s obesity and diabetes market is projected to hit $150 billion annually  
• Mounjaro’s adoption reflects rising demand for lifestyle-driven therapies among urban consumers  

Looking ahead  
Mounjaro’s success marks a turning point in India’s drug market, with lifestyle and chronic disease treatments gaining dominance over traditional antibiotics.

Sources: India Today, LiveMint, Business Standard, Hindustan Times